TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Optimal PEEP in NSICU Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (age \>/= 18) admitted to the Neuro ICU of UNC Hospital requiring mechanical ventilation and with ICP monitoring in place.~Exclusion Criteria:~1. Pneumothorax or pneumomediastinum~2. Life expectancy \< 24 hours or expected to require mechanical ventilation for \< 24 hours~3. Condition that precludes placement of an esophageal balloon \[esophageal or nasopharyngeal pathology preventing insertion of the esophageal balloon catheter (esophageal ulcerations, tumors, diverticulitis, bleeding varices or in patients with sinusitis, epistaxis or recent nasopharyngeal surgery), severe thrombocytopenia (platelet count \< 30) or coagulopathy (INR \> 3 or on oral anticoagulants).~4. Pre-enrollment ICP \> 20 mm Hg~5. Pre-enrollment CPP \< 60 mm Hg~6. Planned change in the external ventricular drain set point during the pre-intervention, intervention or post-intervention periods~7. Incarceration~8. Variation in ICP of \> 2 cm H2O in the hour prior to intervention.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Esophageal Balloon catheter (Type: EXPERIMENTAL): All patients will have an esophageal balloon catheter inserted into their nare while upright (head of bed \> 30 degrees) to a depth slightly more than the estimated distance from the lower sternum to the back of the ear (typically around 60 cm). Gastric positioning will be confirmed with abdominal compression testing and the catheter then retracted 10 - 20 cm into the lower esophagus. Placement will be confirmed with the presence of cardiac oscillations on the esophageal probe. The probe will then be secured to the patient's nasal opening using tape.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: INTUIT Hip Fracture Outcome Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Unilateral unstable intertrochanteric hip fracture without other lower extremity fractures.~* Community and household ambulators with or without assistive devices.~* Age 50 years or greater.~Exclusion Criteria:~* Stable intertrochanteric hip fracture.~* Bilateral or two or more lower extremity fractures.~* Non-functional ambulators or non-ambulators.~* Age less than 50 years.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of hepatocellular carcinoma (HCC) according to the European Association for the Study of the Liver (EASL) criteria~  * Advanced disease~ * Must be morphologically evaluable~* HCC not accessible to other treatment (e.g., surgery, radiofrequency, or chemoembolization) and can not benefit from antiangiogenic therapy~* CLIP score ≤ 3 (except for patients with tumors invading more than 50% of tumor volume)~* Child-Pugh cirrhosis score between B7 and B9, meeting the following criteria:~  * Diagnosed clinically, biologically (e.g., prothrombin time, platelets, or albumin), endoscopically (signs of portal hypertension) and morphologically (dysmorphic liver on ultrasound or CT scan), or by liver biopsy~* Not a candidate for transplantation and has not received a liver transplant~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Life expectancy ≥ 3 months~* Platelet count ≥ 50,000/mm\^3~* Neutrophil count ≥ 1,500/mm\^3~* Creatinine clearance ≥ 60 mL/min~* GFR ≥ 30 mL/min~* Serum cholesterol ≤ 350 mg/dL~* Triglycerides ≤ 300 mg/dL~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for more than 2 months after completion of study therapy~* No history of other cancer on treatment~* No cardiopulmonary disease impairment, including a history of stable or unstable angina or myocardial infarction~* No active infection except for viral hepatitis~* No HIV positivity~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* At least 2 weeks since prior inhibitors or inducers of P-glycoprotein, CYP3A4, or CYP3A5~* At least 4 weeks since prior surgery, radiotherapy (except radiotherapy to the bone), transarterial chemoembolization, immunotherapy, or other investigational drug for HCC~* At least 6 months since prior chemotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Temsirolimus (Type: OTHER): Temsirolimus

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Kypho-IORT vs. EBRT in Spinal Metastases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 50 years~* Karnofsky Index ≥ 60~* Initial pain score using the VAS ≥ 3 under standard pain medication~* Histological or by imaging proven painful osteolytic metastases (max. 4 treatable vertebrae) of the thoracic/lumbar spine, which are accessible for Kypho-IORT~* Written informed consent obtained~* Exclusion Criteria:~* Previous local treatment (irradiation, surgery)~* Cranial site of the metastasis above T4~* Pathological fracture with sintering \>50%~* Purely osteoblastic metastasis~* Intraspinal extension~* Erosion of the bony borders of the vertebra which make a cement filling difficult, rated by the treating surgeon~* Tumor expansion to dorsal vertebral structures (pedicle, lamina)~* Pregnancy/lactation

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Kypho-IORT (Type: EXPERIMENTAL): balloon kyphoplasty/vertebroplasty + intraoperative radiotherapy
- Arm B: EBRT (Type: ACTIVE_COMPARATOR): external beam radiotherapy with 30 Gy during 10 days (3 Gy/day)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Aerobic Exercise in Patients Receiving Chemotherapy for Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Patients with cancer scheduled to receive 4-6 courses of an anthracycline-based chemotherapy~PATIENT CHARACTERISTICS:~* Able to pedal a stationary bicycle~* No severe hypertension (systolic blood pressure \> 220 mm Hg or diastolic blood pressure \>120 mm Hg)~* No atrial fibrillation with an uncontrolled ventricular response~* No ventricular arrhythmias~* No unstable angina~* No acute myocardial infarction within the past 28 days of enrollment~* No severe valvular heart disease~* No severe (exercise-limiting) peripheral vascular disease~* No severe pulmonary disease~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- standard of care (Type: NO_INTERVENTION): normal anthracycline therapy
- exercise program (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation of IPI-493 in Hematologic Malignancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* \>/=18 years old~* ECOG 0-1~* confirmed hematological malignancy~* refractory to available therapy or for which no therapy is available~* adequate hepatic, renal function~Exclusion Criteria:~* active CNS malignancy~* prolonged QT interval~* significant GI/liver disease~* other serious concurrent illness or medical condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IPI-493 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Nabilone in Cannabis Users With PTSD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Current cannabis use~* PTSD symptoms~* Able to give informed consent and comply with study procedures~* Women who are normally cycling and practicing an effective form of birth control other than hormonal contraceptives~Exclusion Criteria:~* Meeting criteria for certain current psychiatric disorders~* Clinical laboratory tests outside of normal limits~* History of clinically significant cardiac or respiratory diagnoses~* Current parole or probation~* Women who are currently pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Nabilone (Type: EXPERIMENTAL): Nabilone capsules (4 mg)
- Propranolol (Type: ACTIVE_COMPARATOR): Propranolol capsules (40mg)
- Smoked cannabis (Type: EXPERIMENTAL): (0.0 and 5.6% THC)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Outpatient Neutropenic Diet Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Newly diagnosed patients with acute myelogenous leukemia (AML), acute lymphocytic leukemia ( ALL), or myelodysplastic syndrome (MDS) receiving induction chemotherapy or AML, ALL or MDS patients who are in remission receiving consolidation chemotherapy.~2. Patients who will be receiving myelosuppressive chemotherapy for their disease.~3. Patients who will be able to stay in the Houston area for at least 4 weeks.~4. Patients who can speak either English or Spanish.~Exclusion Criteria:~1. Patients who present with an active infection such as pneumonia, bacteremia, urine, c. difficile or cellulitis infection.~2. Patients who are unable to understand the diet questionnaire which will be written in either English or Spanish.~3. Patients who are admitted to the protective environment.~4. Patients who are younger than age 18 will not be entered in the study.~5. Pregnant patients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Raw Group (Type: OTHER): Participants will eat cooked food and the addition of raw fruits and vegetables.
- Cooked Group (Type: OTHER): Participants will eat only cooked foods.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Atrial Fibrillation Trial to Evade Recurrence: effectS of Hiit Before electrO-Cardioversion for 3-weeKs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Persistent atrial fibrillation~2. Eligible and scheduled for electro-cardioversion at UOHI~3. Rate controlled with a resting ventricular rate of equal to or less than 100bpm~4. Between 18-85 years of age~5. Owns a Smartphone~6. Physically able to participate in exercise~7. Willing and able to provide written, informed consent~8. Willing and able to return for follow-up visits~9. Willing and able to provide daily ECG recordings using the AliveCor system for the duration of the study.~Exclusion Criteria:~1. Participating in routine exercise training (more than two times per week) in the past 3 months~2. Atrial Flutter secondary to ablation~3. Unstable angina~4. Diagnosed with severe mitral or aortic stenosis, hypertrophic obstructive cardiomyopathy~5. Pregnant, lactating or planning to become pregnant during the study period~6. Diagnosed with rheumatic heart disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- High-intensity interval training (HIIT) (Type: EXPERIMENTAL): Participants in the HIIT group will receive 3-weeks of tri-weekly supervised exercise sessions at the University of Ottawa Heart Institute prior to their scheduled electro-cardioversion. The session will last 23 minutes in duration and consist of a 2-minute warm-up at 50% of peak power output (PPO), 2 x 8-minute interval training blocks of 30 seconds at 80-100% of PPO interspersed with 30-seconds of active recovery and a 1-minute cool down at 25 % of PPO. The sessions will be lead by a Registered Kinesiologist.
- Usual Care Control (Type: NO_INTERVENTION): Participants assigned to the control group will have usual care, which involves no behavioural interventions leading up to their electro-cardioversion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transapical Transcatheter Treatment Versus Conventional Surgery in Patients With Native Aortic Valve Stenosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Significant aortic valve stenosis (valve area \< 1cm2)~* Age \> 75 (years Aarhus University Hospital, Skejby)~* Age \> 80 years (other participating centres)~* Operable by conventional surgery AND transapical stent valve implantation~* Expected survival \> 1 year following successful treatment~* Accept of participation and in follow-up investigations after adequate information~* Informed consent~Exclusion Criteria:~* Coronary artery disease requiring PCI or CABG~* Earlier cardiac surgery~* Myocardial infarction within 24 hours~* Kidney failure requiring any dialysis~* Ongoing infection~* Acute surgery~* Allergy to ASA or Clopidogrel

- Gender: ALL
- Minimum Age: 75 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conventional Aortic Valve Surgery (Type: ACTIVE_COMPARATOR): Insertion of a biological valve
- Transapical Aortic Valve Implantation (Type: EXPERIMENTAL): Transapical implantation of an Edwards SAPIENtm valve

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF?

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documented HIV-1 infection by means of any one of the following:~Documentation of HIV diagnosis in the medical record by a licensed health care provider; OR HIV-1 RNA detection by a licensed HIV-1 RNA assay demonstrating \>1000 RNA copies/mL; OR any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 Western blot confirmation or HIV rapid Multispot antibody differentiation assay.~* On an Integrase Strand Transfer Inhibitor (INSTI) based regimen for at least 1 year and less than 5 years prior to screening~* Significant weight gain since initiation of the INSTI-based regimen (\>10% of baseline body weight)~* Viral load of \<200 copies/mL for \> 6 consecutive months prior to screening (single viral blips \<200 copies/mL accepted if re-suppressed)~* Documentation of weight, glycemia, cholesterol, and blood pressure (BP) history within the last year.~* Signed Informed Consent Form (Appendix B) and willing to comply with the protocol.~* Using proper contraception if of child bearing age and potential.~Exclusion Criteria:~* Pregnancy or desire to become pregnant within the next year~* Failure to use adequate contraception during the study if of child-bearing potential.~* Any underlying documented ART resistance to doravirine, tenofovir disoproxil fumarate, or lamivudine~* Prior virologic failure~* Concomitant drugs that interact with doravirine~* Initiated on concomitant drugs known to cause weight gain within the last 6 months (i.e. antidepressants and antipsychotics)~* Concomitant drugs known to cause nephrotoxicity~* History of renal toxicity or renal events while on TDF therapy.~* Creatinine clearance (CrCL) \< 50 mL/min~* Inability to read/understand English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DOR/3TC/TDF (Type: EXPERIMENTAL): 100mg of doravirine (DOR), 300mg of lamivudine (3TC), and 300mg of tenofovir disoproxil fumarate (TDF)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~To be eligible for inclusion into the study, a patient must meet the following criteria:~* Subject has clinically confirmed diagnosis of active AD;~* Subject has chronic pruritus related to AD;~* Subject has moderate to severe pruritus;~* Female subject is not pregnant or nursing during any period of the study.~Key Exclusion Criteria:~A patient will be excluded from the study if any of the following criteria are met:~* Subject has clinically infected AD;~* Subject has pruritus attributed to a cause other than AD;~* Subject has any clinically significant medical condition or physical/laboratory/ECG/vital signs abnormality that would, in the opinion of the investigator, put the subject at undue risk or interfere with interpretation of study results.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Difelikefalin 0.25 mg tablets plus TCS cream (Type: EXPERIMENTAL): Oral difelikefalin tablets administered twice daily. TCS cream applied by study subjects to skin lesions once a day until control is achieved, then as needed.
- Difelikefalin 0.5 mg tablets plus TCS cream (Type: EXPERIMENTAL): Oral difelikefalin tablets administered twice daily. TCS cream applied by study subjects to skin lesions once a day until control is achieved, then as needed.
- Placebo tablets plus TCS cream (Type: ACTIVE_COMPARATOR): Oral placebo tablets administered twice daily. TCS cream applied by study subjects to skin lesions once a day until control is achieved, then as needed
- Placebo tablets plus Vehicle cream (Part A only) (Type: PLACEBO_COMPARATOR): Oral placebo tablets administered twice daily. Vehicle cream applied by study subjects to skin lesions once a day until control is achieved, then as needed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy